Quick Answer
SUTRO BIOPHARMA, INC. reported Diluted EPS of $22.49 per share (loss) for fiscal year 2025.
SUTRO BIOPHARMA, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$22.49 | +23.5% |
| 2024 | -$29.40 | -1551.7% |
| 2023 | -$1.78 | +24.3% |
| 2022 | -$2.35 | -2.6% |
| 2021 | -$2.29 | -131.3% |
| 2020 | -$0.99 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.67 | -13.6% | -378.6% |
| June 30, 2025 | -$0.14 | +76.3% | +84.6% |
| March 31, 2025 | -$0.91 | -54.2% | -54.2% |
| September 30, 2024 | -$0.59 | +27.2% | +0.0% |
| June 30, 2024 | -$0.59 | +7.8% | +0.0% |
| March 31, 2024 | -$0.59 | +30.6% | +27.2% |
| September 30, 2023 | -$0.81 | -118.9% | -26.6% |
| June 30, 2023 | -$0.64 | -16.4% | +24.7% |
- SUTRO BIOPHARMA, INC. showed an increase of +23.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, SUTRO BIOPHARMA, INC.’s diluted eps has declined by 2171.7% (from $0.99 per share (loss) to $22.49 per share (loss)).
- The most recent figure is from SUTRO BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: